BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 24074533)

  • 1. Heterogeneity of ERG expression in core needle biopsies of patients with early prostate cancer.
    Mertz KD; Horcic M; Hailemariam S; D'Antonio A; Dirnhofer S; Hartmann A; Agaimy A; Eppenberger-Castori S; Obermann E; Cathomas G; Bubendorf L
    Hum Pathol; 2013 Dec; 44(12):2727-35. PubMed ID: 24074533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneity of PTEN and ERG expression in prostate cancer on core needle biopsies: implications for cancer risk stratification and biomarker sampling.
    Shah RB; Bentley J; Jeffery Z; DeMarzo AM
    Hum Pathol; 2015 May; 46(5):698-706. PubMed ID: 25724568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies.
    Tomlins SA; Palanisamy N; Siddiqui J; Chinnaiyan AM; Kunju LP
    Arch Pathol Lab Med; 2012 Aug; 136(8):935-46. PubMed ID: 22849743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The utility of ERG/P63 double immunohistochemical staining in the diagnosis of limited cancer in prostate needle biopsies.
    Yaskiv O; Zhang X; Simmerman K; Daly T; He H; Falzarano S; Chen L; Magi-Galluzzi C; Zhou M
    Am J Surg Pathol; 2011 Jul; 35(7):1062-8. PubMed ID: 21623182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with "atypical glands suspicious for cancer".
    He H; Magi-Galluzzi C; Li J; Carver P; Falzarano S; Smith K; Rubin MA; Zhou M
    Am J Surg Pathol; 2011 Apr; 35(4):608-14. PubMed ID: 21383613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The expression profile and heterogeneity analysis of ERG in 633 consecutive prostate cancers from a single center.
    Nie L; Pan X; Zhang M; Yin X; Gong J; Chen X; Xu M; Zhou Q; Chen N
    Prostate; 2019 Jun; 79(8):819-825. PubMed ID: 30900303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrafocal heterogeneity of ERG protein expression and gene fusion pattern in prostate cancer.
    Suh JH; Park JH; Lee C; Moon KC
    Prostate; 2017 Oct; 77(14):1438-1445. PubMed ID: 28845585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
    Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
    Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of ERG protein, a prostate cancer specific marker, in high grade prostatic intraepithelial neoplasia (HGPIN): lack of utility to stratify cancer risks associated with HGPIN.
    He H; Osunkoya AO; Carver P; Falzarano S; Klein E; Magi-Galluzzi C; Zhou M
    BJU Int; 2012 Dec; 110(11 Pt B):E751-5. PubMed ID: 23046279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ERG protein expression over time: from diagnostic biopsies to radical prostatectomy specimens in clinically localised prostate cancer.
    Berg KD; Brasso K; Thomsen FB; Røder MA; Holten-Rossing H; Toft BG; Iversen P; Vainer B
    J Clin Pathol; 2015 Oct; 68(10):788-94. PubMed ID: 26060265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.
    Mosquera JM; Mehra R; Regan MM; Perner S; Genega EM; Bueti G; Shah RB; Gaston S; Tomlins SA; Wei JT; Kearney MC; Johnson LA; Tang JM; Chinnaiyan AM; Rubin MA; Sanda MG
    Clin Cancer Res; 2009 Jul; 15(14):4706-11. PubMed ID: 19584163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.
    Cornu JN; Cancel-Tassin G; Egrot C; Gaffory C; Haab F; Cussenot O
    Prostate; 2013 Feb; 73(3):242-9. PubMed ID: 22821767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clonal evaluation of prostate cancer foci in biopsies with discontinuous tumor involvement by dual ERG/SPINK1 immunohistochemistry.
    Fontugne J; Davis K; Palanisamy N; Udager A; Mehra R; McDaniel AS; Siddiqui J; Rubin MA; Mosquera JM; Tomlins SA
    Mod Pathol; 2016 Feb; 29(2):157-65. PubMed ID: 26743468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Foamy gland carcinoma of the prostate in needle biopsy: incidence, Gleason grade, and comparative α-methylacyl-CoA racemase vs. ERG expression.
    Warrick JI; Humphrey PA
    Am J Surg Pathol; 2013 Nov; 37(11):1709-14. PubMed ID: 23797726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry.
    Schelling LA; Williamson SR; Zhang S; Yao JL; Wang M; Huang J; Montironi R; Lopez-Beltran A; Emerson RE; Idrees MT; Osunkoya AO; Man YG; Maclennan GT; Baldridge LA; Compérat E; Cheng L
    Hum Pathol; 2013 Oct; 44(10):2227-33. PubMed ID: 23850495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Marked heterogeneity of ERG expression in large primary prostate cancers.
    Minner S; Gärtner M; Freudenthaler F; Bauer M; Kluth M; Salomon G; Heinzer H; Graefen M; Bokemeyer C; Simon R; Sauter G; Schlomm T; Wilczak W
    Mod Pathol; 2013 Jan; 26(1):106-16. PubMed ID: 22899295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical expression of Ets-related gene-transcriptional factor in adenocarcinoma prostate and its correlation with Gleason score.
    Mannan R; Bhasin TS; Manjari M; Singh G; Bhatia PK; Sharma S
    Indian J Pathol Microbiol; 2016; 59(4):489-495. PubMed ID: 27721279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic role of ERG immunopositivity in prostatic acinar adenocarcinoma: a study including 454 cases and review of the literature.
    Xu B; Chevarie-Davis M; Chevalier S; Scarlata E; Zeizafoun N; Dragomir A; Tanguay S; Kassouf W; Aprikian A; Brimo F
    Hum Pathol; 2014 Mar; 45(3):488-97. PubMed ID: 24406017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined analysis of TMPRSS2-ERG and TERT for improved prognosis of biochemical recurrence in prostate cancer.
    Sabaliauskaite R; Jarmalaite S; Petroska D; Dasevicius D; Laurinavicius A; Jankevicius F; Lazutka JR
    Genes Chromosomes Cancer; 2012 Aug; 51(8):781-91. PubMed ID: 22505341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity of ERG expression in prostate cancer: a large section mapping study of entire prostatectomy specimens from 125 patients.
    Tsourlakis MC; Stender A; Quaas A; Kluth M; Wittmer C; Haese A; Graefen M; Steurer S; Simon R; Korbel J; Weischenfeldt J; Huland H; Sauter G; Schlomm T; Minner S
    BMC Cancer; 2016 Aug; 16():641. PubMed ID: 27530104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.